Compare AMLX & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMLX | EFC |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | 500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2021 | N/A |
| Metric | AMLX | EFC |
|---|---|---|
| Price | $13.90 | $11.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $20.11 | $14.55 |
| AVG Volume (30 Days) | 867.2K | ★ 1.6M |
| Earning Date | 03-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 13.27% |
| EPS Growth | ★ 65.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $380,786,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.05 |
| P/E Ratio | ★ N/A | $9.50 |
| Revenue Growth | ★ 1612.94 | N/A |
| 52 Week Low | $3.11 | $11.12 |
| 52 Week High | $17.49 | $14.12 |
| Indicator | AMLX | EFC |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 45.62 |
| Support Level | $13.36 | $11.57 |
| Resistance Level | $15.37 | $14.00 |
| Average True Range (ATR) | 0.74 | 0.26 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 48.17 | 66.47 |
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. It acquires reverse mortgage loans both through its origination activities and through secondary market purchases.